



# CHEPLAPHARM ACQUIRES GLOBAL RIGHTS TO QUESTRAN® FROM BRISTOL-MYERS SQUIBB

*CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.*

QUESTRAN® is a prescription drug that is registered in 20 countries worldwide - France, United Kingdom, Italy, Brazil and Germany being the top 5 countries.

Containing the active ingredient Cholestyramine, QUESTRAN® is mainly used to reduce the risk of heart attack and stroke in patients with primary hypercholesterolemia.

“With the acquisition and integration of QUESTRAN® into our **product portfolio**, we do not only continue the very successful cooperation with Bristol-Myers Squibb, but we also reinforce our International Footprint in the respective territories”, said CEO Sebastian F. Braun.

After years of successful development of the global partner network, CHEPLAPHARM further continues its long-term success story by scaling the business model.

## About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international Buy And Build Strategy.

Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates.

CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe for years with projected annual sales of 350 million euros in 2018.

Please refer to [www.cheplapharm.com](http://www.cheplapharm.com) for additional information.

## Press Office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)